The dual role of tumor necrosis factor (TNF) in cancer biology

Current Medicinal Chemistry

Volumn 17, Issue 29, 2010, Pages 3337-3352

  Bertazza, L ^a   Mocellin, S ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Biology; Cancer; Therapy; TNF; Tumor necrosis factor

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DOXORUBICIN; GAMMA INTERFERON; MELPHALAN; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGY; CANCER THERAPY; CAPILLARY LEAK SYNDROME; CELL DEATH; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; GENETIC POLYMORPHISM; HUMAN; HYPOTENSION; LOW DRUG DOSE; MELANOMA; NEOPLASM; SARCOMA; SHOCK; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; TUMOR PROMOTION;

EID: 77957969757     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793176339     Document Type: Article

References (222)

1. Lejeune, F.J.; Liénard, D.; Matter, M.; Rüegg, C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun., 2006, 6, 6.
2. Rosenberg, S.A. Principles and practice of the biologic therapy of cancer, Lippincott Williams & Wilkins: 2000.
3. Pfeffer, K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev., 2003, 14, 185-91.
4. Carswell, E.A.; Old, L.J.; Kassel, R.L.; Green, S.; Fiore, N.; Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A., 1975, 72, 3666-70.
5. Coley, W. Further observations upon the treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases. Bull. Johns Hopkins Hosp., 1896, 7, 157.
6. Beutler, B.; Greenwald, D.; Hulmes, J.D.; Chang, M.; Pan, Y.C.; Mathison, J.; Ulevitch, R.; Cerami, A. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature, 1985, 316, 552-4.
7. Takeda, K.; Iwamoto, S.; Sugimoto, H.; Takuma, T.; Kawatani, N.; Noda, M.; Masaki, A.; Morise, H.; Arimura, H.; Konno, K. Identity of differentiation inducing factor and tumour necrosis factor. Nature, 1986, 323, 338-40.
8. Shirai, T.; Yamaguchi, H.; Ito, H.; Todd, C.W.; Wallace, R.B. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature, 1985, 313, 803-6.
9. Lejeune, F.J.; Ruegg, C.; Lienard, D. Clinical applications of TNFalpha in cancer. Curr. Opin. Immunol., 1998, 10, 573-80.
10. Oppenheim, J.; Feldmann, M. Cytokine Reference, Academic Press 2000.
11. Bemelmans, M.H.; van Tits, L.J.; Buurman, W.A. Tumor necrosis factor: function, release and clearance. Crit. Rev. Immunol., 1996, 16, 1-11.
12. Aggarwal, B. Signaling pathways of the TNF superfamily: a double edged sword. Nat. Rev. Immunol., 2003, 3, 745-56.
13. Chen, G.; Goeddel, D.V. TNF-R1 signaling: a beautiful pathway. Science, 2002, 296, 1634-5.
14. Ghosh, S.; Karin, M. Missing pieces in the NF-kappaB puzzle. Cell, 2002, 109(Suppl), S81-96.
15. Li, X.; Yang, Y.; Ashwell, J.D. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature, 2002, 416, 345-7.
16. Leist, M.; Jaattela, M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell Biol., 2001, 2, 589-98.
17. Du, C.; Fang, M.; Li, Y.; Li, L.; Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 2000, 102, 33-42.
18. Foghsgaard, L.; Wissing, D.; Mauch, D.; Lademann, U.; Bastholm, L.; Boes, M.; Elling, F.; Leist, M.; Jaattela, M. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J. Cell Biol., 2001, 153, 999-1010.
19. Locksley, R.M.; Killeen, N.; Lenardo, M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 2001, 104, 487-501.
20. Kim, J.W.; Choi, E.J.; Joe, C.O. Activation of death-inducing signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP. Oncogene, 2000, 19, 4491-9.
21. Varfolomeev, E.E.; Ashkenazi, A. Tumor necrosis factor: an apoptosis JuNKie? Cell, 2004, 116, 491-7.
22. Orlowski, R.Z.; Baldwin, A.S., Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med., 2002, 8, 385-9.
23. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J.L.; Schroter, M.; Burns, K.; Mattmann, C.; Rimoldi, D.; French, L.E.; Tschopp, J. Inhibition of death receptor signals by cellular FLIP. Nature, 1997, 388, 190-5.
24. Jaattela, M.; Benedict, M.; Tewari, M.; Shayman, J.A.; Dixit, V.M. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene, 1995, 10, 2297-305.
25. Fulda, S.; Kufer, M.U.; Meyer, E.; van Valen, F.; Dockhorn-Dworniczak, B.; Debatin, K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene, 2001, 20, 5865-77.
26. Aggarwal, B.B. Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappaB. Ann. Rheum. Dis., 2000, 59(Suppl 1), i6-16.
27. Gulbins, E.; Grassme, H. Ceramide and cell death receptor clustering. Biochim. Biophys. Acta, 2002, 1585, 139-45.
28. De Nadai, C.; Sestili, P.; Cantoni, O.; Lievremont, J.P.; Sciorati, C.; Barsacchi, R.; Moncada, S.; Meldolesi, J.; Clementi, E. Nitric oxide inhibits tumor necrosis factor-alpha-induced apoptosis by reducing the generation of ceramide. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 5480-5.
29. Liu, B.; Andrieu-Abadie, N.; Levade, T.; Zhang, P.; Obeid, L.M.; Hannun, Y.A. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J. Biol. Chem., 1998, 273, 11313-20.
30. Fehrenbacher, N.; Gyrd-Hansen, M.; Poulsen, B.; Felbor, U.; Kallunki, T.; Boes, M.; Weber, E.; Leist, M.; Jaattela, M. Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res., 2004, 64, 5301-10.
31. Polunovsky, V.A.; Wendt, C.H.; Ingbar, D.H.; Peterson, M.S.; Bitterman, P.B. Induction of endothelial cell apoptosis by TNF alpha: modulation by inhibitors of protein synthesis. Exp. Cell Res., 1994, 214, 584-94.
32. Eggermont, A.M.; de Wilt, J.H.; ten Hagen, T.L. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol., 2003, 4, 429-37.
33. Palladino, M.A., Jr.; Shalaby, M.R.; Kramer, S.M.; Ferraiolo, B.L.; Baughman, R.A.; Deleo, A.B.; Crase, D.; Marafino, B.; Aggarwal, B.B.; Figari, I.S.; et al. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol., 1987, 138, 4023-32.
34. Shimomura, K.; Manda, T.; Mukumoto, S.; Kobayashi, K.; Nakano, K.; Mori, J. Recombinant human tumor necrosis factor-alpha: thrombus formation is a cause of anti-tumor activity. Int. J. Cancer, 1988, 41, 243-7.
35. Van de Wiel, P.A.; Bloksma, N.; Kuper, C.F.; Hofhuis, F.M.; Willers, J.M. Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity. J. Pathol., 1989, 157, 65-73.
36. Furrer, M.; Altermatt, H.J.; Ris, H.B.; Althaus, U.; Ruegg, C.; Lienard, D.; Lejeune, F.J. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system. Melanoma Res., 1997, 7(Suppl 2), S43-9.
37. Balkwill, F.R.; Lee, A.; Aldam, G.; Moodie, E.; Thomas, J.A.; Tavernier, J.; Fiers, W. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res., 1986, 46, 3990-3.
38. Fajardo, L.F.; Kwan, H.H.; Kowalski, J.; Prionas, S.D.; Allison, A.C. Dual role of tumor necrosis factor-alpha in angiogenesis. Am. J. Pathol., 1992, 140, 539-44.
39. Watanabe, N.; Niitsu, Y.; Umeno, H.; Kuriyama, H.; Neda, H.; Yamauchi, N.; Maeda, M.; Urushizaki, I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res., 1988, 48, 2179-83.
40. Naredi, P.L.; Lindner, P.G.; Holmberg, S.B.; Stenram, U.; Peterson, A.; Hafstrom, L.R. The effects of tumour necrosis factor alpha on the vascular bed and blood flow in an experimental rat hepatoma. Int. J. Cancer, 1993, 54, 645-9.
41. Mule, J.J.; Asher, A.; McIntosh, J.; Lafreniere, R.; Shiloni, E.; Lefor, A.; Reichert, C.M.; Rosenberg, S.A. Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: tumor size influences the response to therapy. Cancer Immunol. Immunother., 1988, 26, 202-8.
42. van Etten, B.; de Vries, M.R.; van, I.M.G.; Lans, T.E.; Guetens, G.; Ambagtsheer, G.; van Tiel, S.T.; de Boeck, G.; de Bruijn, E.A.; Eggermont, A.M.; ten Hagen, T.L. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNFalpha-based isolated hepatic perfusion. Br. J. Cancer, 2003, 88, 314-9.
43. Olieman, A.F.; van Ginkel, R.J.; Hoekstra, H.J.; Mooyaart, E.L.; Molenaar, W.M.; Koops, H.S. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann. Surg. Oncol., 1997, 4, 64-9.
44. Huang, X.; Molema, G.; King, S.; Watkins, L.; Edgington, T.S.; Thorpe, P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 1997, 275, 547-50.
45. Zhang, Y.; Deng, Y.; Wendt, T.; Liliensiek, B.; Bierhaus, A.; Greten, J.; He, W.; Chen, B.; Hach-Wunderle, V.; Waldherr, R.; Ziegler, R.; Mannel, D.; Stern, D.M.; Nawroth, P.P. Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factor-induced tissue factor expression and fibrin deposition in mouse meth-A sarcoma. J. Clin. Invest., 1996, 97, 2213-24.
46. Bierhaus, A.; Zhang, Y.; Deng, Y.; Mackman, N.; Quehenberger, P.; Haase, M.; Luther, T.; Muller, M.; Bohrer, H.; Greten, J.; et al. Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. J. Biol. Chem., 1995, 270, 26419-32.
47. Napoleone, E.; Di Santo, A.; Lorenzet, R. Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. Blood, 1997, 89, 541-9.
48. Lewis, J.C.; Jones, N.L.; Hermanns, M.I.; Rohrig, O.; Klein, C.L.; Kirkpatrick, C.J. Tissue factor expression during coculture of endothelial cells and monocytes. Exp. Mol. Pathol., 1995, 62, 207-18.
49. Vandenabeele, P.; Declercq, W.; Vercammen, D.; Van de Craen, M.; Grooten, J.; Loetscher, H.; Brockhaus, M.; Lesslauer, W.; Fiers, W. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J. Exp. Med., 1992, 176, 1015-24.
50. Gregory, S.A.; Morrissey, J.H.; Edgington, T.S. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol. Cell Biol., 1989, 9, 2752-5.
51. Stoelcker, B.; Ruhland, B.; Hehlgans, T.; Bluethmann, H.; Luther, T.; Mannel, D.N. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am. J. Pathol., 2000, 156, 1171-6.
52. Ruegg, C.; Yilmaz, A.; Bieler, G.; Bamat, J.; Chaubert, P.; Lejeune, F.J. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat. Med., 1998, 4, 408-14.
53. Brooks, P.C.; Montgomery, A.M.; Rosenfeld, M.; Reisfeld, R.A.; Hu, T.; Klier, G.; Cheresh, D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994, 79, 1157-64.
54. Mocellin, S.; Provenzano, M.; Rossi, C.R.; Pilati, P.; Scalerta, R.; Nitti, D.; Lise, M. Induction of endothelial nitric oxide synthase expression by melanoma sensitizes endothelial cells to TNF-driven cytotoxicity. Clin. Cancer Res., 2004, in press.
55. Manusama, E.R.; Nooijen, P.T.; Stavast, J.; Durante, N.M.; Marquet, R.L.; Eggermont, A.M. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br. J. Surg., 1996, 83, 551-5.
56. Nooijen, P.T.; Manusama, E.R.; Eggermont, A.M.; Schalkwijk, L.; Stavast, J.; Marquet, R.L.; de Waal, R.M.; Ruiter, D.J. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br. J. Cancer, 1996, 74, 1908-15.
57. Seynhaeve, A.L.; de Wilt, J.H.; van Tiel, S.T.; Eggermont, A.M.; ten Hagen, T.L. Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. Br. J. Cancer, 2002, 86, 1174-9.
58. van der Veen, A.H.; de Wilt, J.H.; Eggermont, A.M.; van Tiel, S.T.; Seynhaeve, A.L.; ten Hagen, T.L. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF- alpha-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects. Br. J. Cancer, 2000, 82, 973-80.
59. Bauer, T.W.; Gutierrez, M.; Dudrick, D.J.; Li, J.; Blair, I.A.; Menon, C.; Fraker, D.L. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan. Surgery, 2003, 133, 420-8.
60. Alexander, H.R., Jr.; Libutti, S.K.; Bartlett, D.L.; Pingpank, J.F.; Kranda, K.; Helsabeck, C.; Beresnev, T. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer, 2002, 95, 730-6.
61. Posner, M.; Lienard, D.; Lejeune, F.J.; Rosenfelder, D.; Kirkwood, J.M. Proc Annu Meet Am Soc Clin Oncol, ed., 1994; Vol. 13, pp. A1351.
62. Seong, J.; Milross, C.G.; Hunter, N.R.; Shin, H.C.; Milas, L. Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha. Anticancer Drugs, 1997, 8, 80-7.
63. Buell, J.F.; Reed, E.; Lee, K.B.; Parker, R.J.; Venzon, D.J.; Amikura, K.; Arnold, S.; Fraker, D.L.; Alexander, H.R. Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells. Ann. Surg. Oncol., 1997, 4, 141-8.
64. Lejeune, F.J. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J. Clin. Invest., 2002, 110, 433-5.
65. de Wilt, J.H.; ten Hagen, T.L.; de Boeck, G.; van Tiel, S.T.; de Bruijn, E.A.; Eggermont, A.M. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br. J. Cancer, 2000, 82, 1000-3.
66. Duan, L.; Aoyagi, M.; Tamaki, M.; Yoshino, Y.; Morimoto, T.; Wakimoto, H.; Nagasaka, Y.; Hirakawa, K.; Ohno, K.; Yamamoto, K. Impairment of both apoptotic and cytoprotective signalings in glioma cells resistant to the combined use of cisplatin and tumor necrosis factor alpha. Clin. Cancer Res., 2004, 10, 234-43.
67. Choi, K.H.; Choi, H.Y.; Ko, J.K.; Park, S.S.; Kim, Y.N.; Kim, C.W. Transcriptional regulation of TNF family receptors and Bcl-2 family by chemotherapeutic agents in murine CT26 cells. J. Cell Biochem., 2004, 91, 410-22.
68. LeBlanc, H.; Lawrence, D.; Varfolomeev, E.; Totpal, K.; Morlan, J.; Schow, P.; Fong, S.; Schwall, R.; Sinicropi, D.; Ashkenazi, A. Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med., 2002, 8, 274-81.
69. Havell, E.A.; Fiers, W.; North, R.J. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J. Exp. Med., 1988, 167, 1067-85.
70. Vujanovic, N.L. Role of TNF family ligands in antitumor activity of natural killer cells. Int. Rev. Immunol., 2001, 20, 415-37.
71. Mocellin, S.; Provenzano, M.; Lise, M.; Nitti, D.; Rossi, C.R. Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma. Int. J. Cancer, 2003, 107, 317-22.
72. Prevost-Blondel, A.; Roth, E.; Rosenthal, F.M.; Pircher, H. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J. Immunol., 2000, 164, 3645-51.
73. Poehlein, C.H.; Hu, H.M.; Yamada, J.; Assmann, I.; Alvord, W.G.; Urba, W.J.; Fox, B.A. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J. Immunol., 2003, 170, 2004-13.
74. Baxevanis, C.N.; Voutsas, I.F.; Tsitsilonis, O.E.; Tsiatas, M.L.; Gritzapis, A.D.; Papamichail, M. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice. Eur. J. Immunol., 2000, 30, 1957-66.
75. Figdor, C.G.; De Vries, I.J.; Lesterhuis, W.J.; Melief, C.J. Dendritic cell immunotherapy: mapping the way. Nat. Med., 2004, 10, 475-80.
76. Balkwill, F. Tumor necrosis factor and cancer. Nat. Rev. Cancer, 2009, 9, 361-71.
77. Balkwill, F. Cancer and the chemokine network. Nat. Rev. Cancer, 2004, 4, 540-50.
78. Kirstein, M.; Baglioni, C. Tumor necrosis factor stimulates proliferation of human osteosarcoma cells and accumulation of c-myc messenger RNA. J. Cell Physiol., 1988, 134, 479-84.
79. Wu, S.; Boyer, C.M.; Whitaker, R.S.; Berchuck, A.; Wiener, J.R.; Weinberg, J.B.; Bast, R.C., Jr. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res., 1993, 53, 1939-44.
80. Ferrajoli, A.; Keating, M.J.; Manshouri, T.; Giles, F.J.; Dey, A.; Estrov, Z.; Koller, C.A.; Kurzrock, R.; Thomas, D.A.; Faderl, S.; Lerner, S.; O'Brien, S.; Albitar, M. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood, 2002, 100, 1215-9.
81. Liu, R.Y.; Fan, C.; Liu, G.; Olashaw, N.E.; Zuckerman, K.S. Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-alpha -supported proliferation of leukemia and lymphoma cell lines. J. Biol. Chem., 2000, 275, 21086-93.
82. Tselepis, C.; Perry, I.; Dawson, C.; Hardy, R.; Darnton, S.J.; McConkey, C.; Stuart, R.C.; Wright, N.; Harrison, R.; Jankowski, J.A. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene, 2002, 21, 6071-81.
83. Humblet, C.; Greimers, R.; Delvenne, P.; Deman, J.; Boniver, J.; Defresne, M.P. Prevention of murine radiogenic thymic lymphomas by tumor necrosis factor or by marrow grafting. J. Natl. Cancer Inst., 1996, 88, 824-31.
84. Moore, R.J.; Owens, D.M.; Stamp, G.; Arnott, C.; Burke, F.; East, N.; Holdsworth, H.; Turner, L.; Rollins, B.; Pasparakis, M.; Kollias, G.; Balkwill, F. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med., 1999, 5, 828-31.
85. Komori, A.; Yatsunami, J.; Suganuma, M.; Okabe, S.; Abe, S.; Sakai, A.; Sasaki, K.; Fujiki, H. Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res., 1993, 53, 1982-5.
86. Suganuma, M.; Okabe, S.; Marino, M.W.; Sakai, A.; Sueoka, E.; Fujiki, H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res., 1999, 59, 4516-8.
87. Jaiswal, M.; LaRusso, N.F.; Burgart, L.J.; Gores, G.J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res., 2000, 60, 184-90.
88. Dhar, A.; Young, M.R.; Colburn, N.H. The role of AP-1, NFkappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Mol. Cell Biochem., 2002, 234-235, 185-93.
89. Arnott, C.H.; Scott, K.A.; Moore, R.J.; Hewer, A.; Phillips, D.H.; Parker, P.; Balkwill, F.R.; Owens, D.M. Tumour necrosis factoralpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene, 2002, 21, 4728-38.
90. Korner, H.; Cretney, E.; Wilhelm, P.; Kelly, J.M.; Rollinghoff, M.; Sedgwick, J.D.; Smyth, M.J. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J. Exp. Med., 2000, 191, 89-96.
91. Arnott, C.H.; Scott, K.A.; Moore, R.J.; Robinson, S.C.; Thompson, R.G.; Balkwill, F.R. Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene, 2004, 23, 1902-10.
92. Knight, B.; Yeoh, G.C.; Husk, K.L.; Ly, T.; Abraham, L.J.; Yu, C.; Rhim, J.A.; Fausto, N. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J. Exp. Med., 2000, 192, 1809-18.
93. Orosz, P.; Echtenacher, B.; Falk, W.; Ruschoff, J.; Weber, D.; Mannel, D.N. Enhancement of experimental metastasis by tumor necrosis factor. J. Exp. Med., 1993, 177, 1391-8.
94. Waterston, A.M.; Salway, F.; Andreakos, E.; Butler, D.M.; Feldmann, M.; Coombes, R.C. TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br. J. Cancer, 2004, 90, 1279-84.
95. Kitakata, H.; Nemoto-Sasaki, Y.; Takahashi, Y.; Kondo, T.; Mai, M.; Mukaida, N. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res., 2002, 62, 6682-7.
96. Malik, S.T.; Naylor, M.S.; East, N.; Oliff, A.; Balkwill, F.R. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur. J. Cancer, 1990, 26, 1031-4.
97. Qin, Z.; Kruger-Krasagakes, S.; Kunzendorf, U.; Hock, H.; Diamantstein, T.; Blankenstein, T. Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J. Exp. Med., 1993, 178, 355-60.
98. Leber, T.M.; Balkwill, F.R. Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br. J. Cancer, 1998, 78, 724-32.
99. Katerinaki, E.; Evans, G.S.; Lorigan, P.C.; MacNeil, S. TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. Br. J. Cancer, 2003, 89, 1123-9.
100. Nabors, L.B.; Suswam, E.; Huang, Y.; Yang, X.; Johnson, M.J.; King, P.H. Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Cancer Res., 2003, 63, 4181-7.
101. Joseph, I.B.; Isaacs, J.T. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J. Natl. Cancer Inst., 1998, 90, 1648-53.
102. Nesbit, M.; Schaider, H.; Miller, T.H.; Herlyn, M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J. Immunol., 2001, 166, 6483-90.
103. Yoshida, S.; Ono, M.; Shono, T.; Izumi, H.; Ishibashi, T.; Suzuki, H.; Kuwano, M. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell Biol., 1997, 17, 4015-23.
104. Cheng, N.; Chen, J. Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism. J. Biol. Chem., 2001, 276, 13771-7.
105. De Cesaris, P.; Starace, D.; Starace, G.; Filippini, A.; Stefanini, M.; Ziparo, E. Activation of Jun N-terminal kinase/stress-activated protein kinase pathway by tumor necrosis factor alpha leads to intercellular adhesion molecule-1 expression. J. Biol. Chem., 1999, 274, 28978-82.
106. Kawai, N.; Tsuji, S.; Tsujii, M.; Ito, T.; Yasumaru, M.; Kakiuchi, Y.; Kimura, A.; Komori, M.; Sasaki, Y.; Hayashi, N.; Kawano, S.; Dubois, R.; Hori, M. Tumor necrosis factor alpha stimulates invasion of Src-activated intestinal cells. Gastroenterology, 2002, 122, 331-9.
107. Mantovani, G.; Maccio, A.; Lai, P.; Massa, E.; Ghiani, M.; Santona, M.C. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin. Oncol., 1998, 25, 45-52.
108. Dalum, I.; Butler, D.M.; Jensen, M.R.; Hindersson, P.; Steinaa, L.; Waterston, A.M.; Grell, S.N.; Feldmann, M.; Elsner, H.I.; Mouritsen, S. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat. Biotechnol., 1999, 17, 666-9.
109. Haslett, P.A. Anticytokine approaches to the treatment of anorexia and cachexia. Semin. Oncol., 1998, 25, 53-7.
110. Tisdale, M.J. Cancer cachexia. Langenbecks Arch. Surg., 2004, 389, 299-305.
111. Michalaki, V.; Syrigos, K.; Charles, P.; Waxman, J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer, 2004, 90, 2312-6.
112. Dosquet, C.; Coudert, M.C.; Lepage, E.; Cabane, J.; Richard, F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin. Cancer Res., 1997, 3, 2451-8.
113. Warzocha, K.; Bienvenu, J.; Ribeiro, P.; Moullet, I.; Dumontet, C.; Neidhardt-Berard, E.M.; Coiffier, B.; Salles, G. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br. J. Cancer, 1998, 77, 2357-62.
114. Dredge, K.; Marriott, J.B.; Dalgleish, A.G. Immunological effects of thalidomide and its chemical and functional analogs. Crit. Rev. Immunol., 2002, 22, 425-37.
115. D'Amato, R.J.; Lentzsch, S.; Anderson, K.C.; Rogers, M.S. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin. Oncol., 2001, 28, 597-601.
116. Marsh, H.P.; Haldar, N.A.; Bunce, M.; Marshall, S.E.; le Monier, K.; Winsey, S.L.; Christodoulos, K.; Cranston, D.; Welsh, K.I.; Harris, A.L. Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br. J. Cancer, 2003, 89, 1096-101.
117. Nakajima, K.; Sasaki, M.; Nojima, D.; Oh, B.R.; Ishii, N.; Miura, K.; Dahiya, R. Tumor necrosis factor-alpha gene mutations and genotype changes in renal cell carcinoma. J. Urol., 2001, 165, 612-5.
118. Oh, B.R.; Sasaki, M.; Perinchery, G.; Ryu, S.B.; Park, Y.I.; Carroll, P.; Dahiya, R. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J. Urol., 2000, 163, 1584-7.
119. Hajeer, A.H.; Lear, J.T.; Ollier, W.E.; Naves, M.; Worthington, J.; Bell, D.A.; Smith, A.G.; Bowers, W.P.; Jones, P.W.; Strange, R.C.; Fryer, A.A. Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas. Br. J. Dermatol., 2000, 142, 441-5.
120. Ho, S.Y.; Wang, Y.J.; Chen, H.L.; Chen, C.H.; Chang, C.J.; Wang, P.J.; Chen, H.H.; Guo, H.R. Increased Risk of Developing Hepatocellular Carcinoma Associated with Carriage of the TNF2 Allele of the -308 Tumor Necrosis Factor-alpha Promoter Gene. Cancer Causes Control., 2004, 15, 657-63.
121. Machado, J.C.; Figueiredo, C.; Canedo, P.; Pharoah, P.; Carvalho, R.; Nabais, S.; Castro Alves, C.; Campos, M.L.; Van Doorn, L.J.; Caldas, C.; Seruca, R.; Carneiro, F.; Sobrinho-Simoes, M. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology, 2003, 125, 364-71.
122. Mestiri, S.; Bouaouina, N.; Ahmed, S.B.; Khedhaier, A.; Jrad, B.B.; Remadi, S.; Chouchane, L. Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer, 2001, 91, 672-8.
123. Gorouhi, F.; Islami, F.; Bahrami, H.; Kamangar, F. Tumournecrosis factor-A polymorphisms and gastric cancer risk: a metaanalysis. Br. J. Cancer, 2008, 98, 1443-51.
124. Davies, F.E.; Rollinson, S.J.; Rawstron, A.C.; Roman, E.; Richards, S.; Drayson, M.; Child, J.A.; Morgan, G.J. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an sociated with an increased risk of myeloma and have an improved progression-free survival after treatment. J. Clin. Oncol., 2000, 18, 2843-51.
125. Warzocha, K.; Ribeiro, P.; Bienvenu, J.; Roy, P.; Charlot, C.; Rigal, D.; Coiffier, B.; Salles, G. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood, 1998, 91, 3574-81.
126. Takeuchi, S.; Takeuchi, N.; Tsukasaki, K.; Bartram, C.R.; Zimmermann, M.; Schrappe, M.; Taguchi, H.; Koeffler, H.P. Genetic polymorphisms in the tumour necrosis factor locus in childhood acute lymphoblastic leukaemia. Br. J. Haematol., 2002, 119, 985-7.
127. Wu, H.C.; Chang, C.H.; Chen, H.Y.; Tsai, F.J.; Tsai, J.J.; Chen, W.C. p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol. Int., 2004, 73, 41-6.
128. Azmy, I.A.; Balasubramanian, S.P.; Wilson, A.G.; Stephenson, T.J.; Cox, A.; Brown, N.J.; Reed, M.W. Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity. Breast Cancer Res., 2004, 6, R395-400.
129. Jang, W.H.; Yang, Y.I.; Yea, S.S.; Lee, Y.J.; Chun, J.H.; Kim, H.I.; Kim, M.S.; Paik, K.H. The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett., 2001, 166, 41-6.
130. Wu, M.S.; Chen, L.T.; Shun, C.T.; Huang, S.P.; Chiu, H.M.; Wang, H.P.; Lin, M.T.; Cheng, A.L.; Lin, J.T. Promoter polymorphisms of tumor necrosis factor-alpha are associated with risk of gastric mucosa-associated lymphoid tissue lymphoma. Int. J. Cancer, 2004, 110, 695-700.
131. Rossi, C.R.; Foletto, M.; Pilati, P.; Mocellin, S.; Lise, M. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin. Oncol., 2002, 29, 400-9.
132. Rossi, C.R.; Mocellin, S.; Pilati, P.; Foletto, M.; Nitti, D.; Lise, M. TNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: state of the art and future trends. J. Immunother., 2003, 26, 291-300.
133. Christoforidis, D.; Martinet, O.; Lejeune, F.J.; Mosimann, F. Isolated liver perfusion for non-resectable liver tumours: a review. Eur. J. Surg. Oncol., 2002, 28, 875-90.
134. Vilcek, J.; Feldmann, M. Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pharmacol. Sci., 2004, 25, 201-9.
135. Kajiwara, K.; Saito, A.; Ogata, S.; Tanihara, M. Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively. Biochim. Biophys. Acta, 2004, 1699, 131-7.
136. Olsen, N.J.; Stein, C.M. New drugs for rheumatoid arthritis. N. Engl. J. Med., 2004, 350, 2167-79.
137. Brown, S.L.; Greene, M.H.; Gershon, S.K.; Edwards, E.T.; Braun, M.M. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum., 2002, 46, 3151-8.
138. Wolfe, F.; Michaud, K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum., 2004, 50, 1740-51.
139. Szlosarek, P.W.; Balkwill, F.R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol., 2003, 4, 565-73.
140. Tsimberidou, A.M.; Waddelow, T.; Kantarjian, H.M.; Albitar, M.; Giles, F.J. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk. Res., 2003, 27, 375-80.
141. Du Bois, J.S.; Trehu, E.G.; Mier, J.W.; Shapiro, L.; Epstein, M.; Klempner, M.; Dinarello, C.; Kappler, K.; Ronayne, L.; Rand, W.; Atkins, M.B. Randomized placebo-controlled clinical trial of highdose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J. Clin. Oncol., 1997, 15, 1052-62.
142. Gerspach, J.; Pfizenmaier, K.; Wajant, H. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors, 2009, 35, 364-72.
143. Ameloot, P.; Brouckaert, P. Production and characterization of receptor-specific TNF muteins. Methods Mol. Med., 2004, 98, 33-46.
144. Sato, T.; Yamauchi, N.; Sasaki, H.; Takahashi, M.; Okamoto, T.; Sakamaki, S.; Watanabe, N.; Niitsu, Y. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration. Cancer Res., 1998, 58, 1677-83.
145. Terlikowski, S.J. Local immunotherapy with rhTNF-alpha mutein induces strong antitumor activity without overt toxicity--a review. Toxicology, 2002, 174, 143-52.
146. Novakovic, S.; Menart, V.; Gaberc-Porekar, V.; Stalc, A.; Sersa, G.; Cemazar, M.; Jezersek, B. New TNF-alpha analogues: a powerful but less toxic biological tool against tumours. Cytokine, 1997, 9, 597-604.
147. Wielockx, B.; Lannoy, K.; Shapiro, S.D.; Itoh, T.; Itohara, S.; Vandekerckhove, J.; Libert, C. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat. Med., 2001, 7, 1202-8.
148. Hohenberger, P.; Latz, E.; Kettelhack, C.; Rezaei, A.H.; Schumann, R.; Schlag, P.M. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Ann. Surg. Oncol., 2003, 10, 562-8.
149. Jacquet, P.; Sugarbaker, P.H. Peritoneal-plasma barrier. Cancer Treat. Res., 1996, 82, 53-63.
150. Rossi, C.R.; Mocellin, S.; Pilati, P.; Foletto, M.; Quintieri, L.; Palatini, P.; Lise, M. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg. Oncol. Clin. N. Am., 2003, 12, 781-94.
151. Behammer, W.; Kluge, M.; Ruschoff, J.; Mannel, D.N. Tumor necrosis factor effects on ascites formation in an experimental tumor model. J. Interferon Cytokine Res., 1996, 16, 403-8.
152. Gutman, M.; Sofer, D.; Lev-Chelouche, D.; Merimsky, O.; Klausner, J.M. Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study. Invasion Metastasis, 1997, 17, 169-75.
153. Bartlett, D.L.; Buell, J.F.; Libutti, S.K.; Reed, E.; Lee, K.B.; Figg, W.D.; Venzon, D.J.; Alexander, H.R. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer, 1998, 83, 1251-61.
154. ten Hagen, T.L.; Seynhaeve, A.L.; van Tiel, S.T.; Ruiter, D.J.; Eggermont, A.M. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int. J. Cancer, 2002, 97, 115-20.
155. Brouckaert, P.; Takahashi, N.; van Tiel, S.T.; Hostens, J.; Eggermont, A.M.; Seynhaeve, A.L.; Fiers, W.; ten Hagen, T.L. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int. J. Cancer, 2004, 109, 442-8.
156. Weichselbaum, R.R.; Kufe, D.W.; Hellman, S.; Rasmussen, H.S.; King, C.R.; Fischer, P.H.; Mauceri, H.J. Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol., 2002, 3, 665-71.
157. Senzer, N.; Mani, S.; Rosemurgy, A.; Nemunaitis, J.; Cunningham, C.; Guha, C.; Bayol, N.; Gillen, M.; Chu, K.; Rasmussen, C.; Rasmussen, H.; Kufe, D.; Weichselbaum, R.; Hanna, N. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J. Clin. Oncol., 2004, 22, 592-601.
158. Bazzoni, F.; Regalia, E. Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNFalpha. Cancer Res., 2001, 61, 1050-7.
159. Xiao, C.W.; Yan, X.; Li, Y.; Reddy, S.A.; Tsang, B.K. Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fasassociated death domain-like interleukin-1beta-converting enzymelike inhibitory protein. Endocrinology, 2003, 144, 623-30.
160. Vasudevan, K.M.; Gurumurthy, S.; Rangnekar, V.M. Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol. Cell Biol., 2004, 24, 1007-21.
161. Zwacka, R.M.; Stark, L.; Dunlop, M.G. NF-kappaB kinetics predetermine TNF-alpha sensitivity of colorectal cancer cells. J. Gene Med., 2000, 2, 334-43.
162. Wang, C.Y.; Cusack, J.C., Jr.; Liu, R.; Baldwin, A.S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med., 1999, 5, 412-7.
163. Lee, K.Y.; Chang, W.; Qiu, D.; Kao, P.N.; Rosen, G.D. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J. Biol. Chem., 1999, 274, 13451-5.
164. Davis, N.B.; Taber, D.A.; Ansari, R.H.; Ryan, C.W.; George, C.; Vokes, E.E.; Vogelzang, N.J.; Stadler, W.M. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J. Clin. Oncol., 2004, 22, 115-9.
165. Papandreou, C.N.; Logothetis, C.J. Bortezomib as a potential treatment for prostate cancer. Cancer Res., 2004, 64, 5036-43.
166. Richardson, P.G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S.V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R.Z.; Kuter, D.; Limentani, S.A.; Lee, S.; Hideshima, T.; Esseltine, D.L.; Kauffman, M.; Adams, J.; Schenkein, D.P.; Anderson, K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med., 2003, 348, 2609-17.
167. An, J.; Sun, Y.P.; Adams, J.; Fisher, M.; Belldegrun, A.; Rettig, M.B. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin. Cancer Res., 2003, 9, 4537-45.
168. Binder, C.; Schulz, M.; Hiddemann, W.; Oellerich, M. Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-alpha-induced apoptosis in MCF-7 and other epithelial tumor cells. Lab. Invest., 1999, 79, 1703-12.
169. Kaku, Y.; Nanri, H.; Sakimura, T.; Ejima, K.; Kuroiwa, A.; Ikeda, M. Differential induction of constitutive and inducible nitric oxide synthases by distinct inflammatory stimuli in bovine aortic endothelial cells. Biochim. Biophys. Acta, 1997, 1356, 43-52.
170. Ganster, R.W.; Taylor, B.S.; Shao, L.; Geller, D.A. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 8638-43.
171. Song, W.; Lu, X.; Feng, Q. Tumor necrosis factor-alpha induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes. Cardiovasc. Res., 2000, 45, 595-602.
172. Kim, Y.M.; Talanian, R.V.; Billiar, T.R. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J. Biol. Chem., 1997, 272, 31138-48.
173. Dimmeler, S.; Haendeler, J.; Nehls, M.; Zeiher, A.M. Suppression of apoptosis by nitric oxide via inhibition of interleukin- 1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J. Exp. Med., 1997, 185, 601-7.
174. Kim, Y.M.; Kim, T.H.; Seol, D.W.; Talanian, R.V.; Billiar, T.R. Nitric oxide suppression of apoptosis occurs in association with an inhibition of Bcl-2 cleavage and cytochrome c release. J. Biol. Chem., 1998, 273, 31437-41.
175. Li, J.; Bombeck, C.A.; Yang, S.; Kim, Y.M.; Billiar, T.R. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. J. Biol. Chem., 1999, 274, 17325-33.
176. Torok, N.J.; Higuchi, H.; Bronk, S.; Gores, G.J. Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9. Cancer Res., 2002, 62, 1648-53.
177. Thomas, W.J.; Thomas, D.L.; Knezetic, J.A.; Adrian, T.E. The role of oxygen-derived free radicals and nitric oxide in cytokineinduced antiproliferation of pancreatic cancer cells. Pancreas, 2002, 24, 161-8.
178. Bulotta, S.; Barsacchi, R.; Rotiroti, D.; Borgese, N.; Clementi, E. Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-alpha. A novel feedback mechanism regulating cell death. J. Biol. Chem., 2001, 276, 6529-36.
179. de Wilt, J.H.; Manusama, E.R.; van Etten, B.; van Tiel, S.T.; Jorna, A.S.; Seynhaeve, A.L.; ten Hagen, T.L.; Eggermont, A.M. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br. J. Cancer, 2000, 83, 1176-82.
180. Hannun, Y.A.; Luberto, C. Ceramide in the eukaryotic stress response. Trends Cell Biol., 2000, 10, 73-80.
181. Garban, H.J.; Bonavida, B. Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha -induced cytotoxicity. J. Biol. Chem., 2001, 276, 8918-23.
182. Obrador, E.; Carretero, J.; Pellicer, J.A.; Estrela, J.M. Possible mechanisms for tumour cell sensitivity to TNF-alpha and potential therapeutic applications. Curr. Pharm. Biotechnol., 2001, 2, 119-30.
183. Liu, R.; Li, B.; Qiu, M. Elevated superoxide production by active H-ras enhances human lung WI-38VA-13 cell proliferation, migration and resistance to TNF-alpha. Oncogene, 2001, 20, 1486-96.
184. Delhalle, S.; Deregowski, V.; Benoit, V.; Merville, M.P.; Bours, V. NF-kappaB-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis. Oncogene, 2002, 21, 3917-24.
185. Giardina, C.; Boulares, H.; Inan, M.S. NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species. Biochim. Biophys. Acta, 1999, 1448, 425-38.
186. Berman, K.S.; Verma, U.N.; Harburg, G.; Minna, J.D.; Cobb, M.H.; Gaynor, R.B. Sulindac enhances tumor necrosis factoralpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. Clin. Cancer Res., 2002, 8, 354-60.
187. Totzke, G.; Schulze-Osthoff, K.; Janicke, R.U. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene, 2003, 22, 8021-30.
188. Yasui, H.; Adachi, M.; Imai, K. Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice. Cancer, 2003, 97, 1412-20.
189. Fulda, S.; Debatin, K.M. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene, 2002, 21, 2295-308.
190. Lienard, D.; Eggermont, A.M.; Koops, H.S.; Kroon, B.; Towse, G.; Hiemstra, S.; Schmitz, P.; Clarke, J.; Steinmann, G.; Rosenkaimer, F.; Lejeune, F.J. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res., 1999, 9, 491-502.
191. Eggermont, A.M.; Schraffordt Koops, H.; Klausner, J.M.; Kroon, B.B.; Schlag, P.M.; Lienard, D.; van Geel, A.N.; Hoekstra, H.J.; Meller, I.; Nieweg, O.E.; Kettelhack, C.; Ben-Ari, G.; Pector, J.C.; Lejeune, F.J. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann. Surg., 1996, 224, 756-64 discussion 64-5.
192. Gnant, M.F.; Berger, A.C.; Huang, J.; Puhlmann, M.; Wu, P.C.; Merino, M.J.; Bartlett, D.L.; Alexander, H.R., Jr.; Libutti, S.K. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res., 1999, 59, 4668-74.
193. Berger, A.C.; Alexander, H.R.; Wu, P.C.; Tang, G.; Gnant, M.F.; Mixon, A.; Turner, E.S.; Libutti, S.K. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte-activating polypeptide II (EMAP-II). Cytokine, 2000, 12, 992-1000.
194. Chopin, V.; Slomianny, C.; Hondermarck, H.; Le Bourhis, X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp. Cell Res., 2004, 298, 560-73.
195. Duverger, V.; Murphy, A.M.; Sheehan, D.; England, K.; Cotter, T.G.; Hayes, I.; Murphy, F.J. The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF). Br. J. Cancer, 2004, 90, 2025-31.
196. Beyaert, R.; Vanhaesebroeck, B.; Suffys, P.; Van Roy, F.; Fiers, W. Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A., 1989, 86, 9494-8.
197. Schotte, P.; Van Loo, G.; Carpentier, I.; Vandenabeele, P.; Beyaert, R. Lithium sensitizes tumor cells in an NF-kappa B-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF). Evidence for a role of the TNF receptor-associated death domain protein. J. Biol. Chem., 2001, 276, 25939-45.
198. Hanada, M.; Feng, J.; Hemmings, B.A. Structure, regulation and function of PKB/AKT--a major therapeutic target. Biochim. Biophys. Acta, 2004, 1697, 3-16.
199. Diarra-Mehrpour, M.; Arrabal, S.; Jalil, A.; Pinson, X.; Gaudin, C.; Pietu, G.; Pitaval, A.; Ripoche, H.; Eloit, M.; Dormont, D.; Chouaib, S. Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death. Cancer Res., 2004, 64, 719-27.
200. Zhang, L.; Himi, T.; Morita, I.; Murota, S. Inhibition of phosphatidylinositol-3 kinase/Akt or mitogen-activated protein kinase signaling sensitizes endothelial cells to TNF-alpha cytotoxicity. Cell Death Differ., 2001, 8, 528-36.
201. Nishida, S.; Yoshioka, S.; Kinoshita-Kimoto, S.; Kotani, M.; Tsubaki, M.; Fujii, Y.; Tomura, T.T.; Irimajiri, K. Pretreatment with PKC inhibitor triggers TNF-alpha induced apoptosis in TNF-alpharesistant B16 melanoma BL6 cells. Life Sci., 2003, 74, 781-92.
202. Bezzi, M.; Hasmim, M.; Bieler, G.; Dormond, O.; Ruegg, C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J. Biol. Chem., 2003, 278, 43603-14.
203. Wajant, H. The role of TNF in cancer. Results Probl. Cell Differ., 2009, 49, 1-15.
204. Sethi, G.; Sung, B.; Aggarwal, B.B. TNF: a master switch for inflammation to cancer. Front Biosci., 2008, 13, 5094-107.
205. Mocellin, S.; Nitti, D. TNF and cancer: the two sides of the coin. Front Biosci., 2008, 13, 2774-83.
206. Anderson, G.M.; Nakada, M.T.; DeWitte, M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol., 2004, 4, 314-20.
207. Tada, Y. J. O.W.; Takenaga, K.; Takiguchi, Y.; Tatsumi, K.; Kuriyama, T.; Tagawa, M. Expression of the TNF-alpha gene on mouse lung carcinoma cells suppresses spontaneous lung metastasis without affecting tumorigenicity. Oncol. Rep., 2002, 9, 585-8.
208. Ortega, A.L.; Carretero, J.; Obrador, E.; Gambini, J.; Asensi, M.; Rodilla, V.; Estrela, J.M. Tumor cytotoxicity by endothelial cells. Impairment of the mitochondrial system for glutathione uptake in mouse B16 melanoma cells that survive after in vitro interaction with the hepatic sinusoidal endothelium. J. Biol. Chem., 2003, 278, 13888-97.
209. Lienard, D.; Eggermont, A.M.; Schraffordt Koops, H.; Kroon, B.B.; Rosenkaimer, F.; Autier, P.; Lejeune, F.J. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNFalpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res., 1994, 4(Suppl 1), 21-6.
210. Fraker, D.L.; Alexander, H.R.; Andrich, M.; Rosenberg, S.A. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J. Clin. Oncol., 1996, 14, 479-89.
211. Rossi, C.R.; Foletto, M.; Mocellin, S.; Pilati, P.; Lise, M. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann. Surg. Oncol., 2004, 11, 173-7.
212. Gutman, M.; Inbar, M.; Lev-Shlush, D.; Abu-Abid, S.; Mozes, M.; Chaitchik, S.; Meller, I.; Klausner, J.M. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer, 1997, 79, 1129-37.
213. Plaat, B.E.; Molenaar, W.M.; Mastik, M.F.; Koudstaal, J.; van den Berg, E.; Koops, H.S.; Hoekstra, H.J. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. Clin. Cancer Res., 1999, 5, 1650-7.
214. Rossi, C.R.; Foletto, M.; Di Filippo, F.; Vaglini, M.; Anza, M.; Azzarelli, A.; Pilati, P.; Mocellin, S.; Lise, M. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer, 1999, 86, 1742-9.
215. Lejeune, F.J.; Pujol, N.; Lienard, D.; Mosimann, F.; Raffoul, W.; Genton, A.; Guillou, L.; Landry, M.; Chassot, P.G.; Chiolero, R.; Bischof-Delaloye, A.; Leyvraz, S.; Mirimanoff, R.O.; Bejkos, D.; Leyvraz, P.F. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur. J. Surg. Oncol., 2000, 26, 669-78.
216. Komdeur, R.; Plaat, B.E.; Hoekstra, H.J.; Molenaar, W.M.; Hollema, H.; van den Berg, E.; Mastik, M.F.; van der Graaf, W.T. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer, 2001, 91, 1940-8.
217. Noorda, E.M.; Vrouenraets, B.C.; Nieweg, O.E.; van Coevorden, F.; van Slooten, G.W.; Kroon, B.B. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer, 2003, 98, 1483-90.
218. Rossi, C.; Mocellin, C.; Pilati, P.; Foletto, M.; Quintieri, L.; Desalvo, G.; Lise, M. Hyperthermic isolated perfusion with low-dose TNFa and doxorubicin for the treatment of limb threatening soft tissue sarcomas: a phase II study. Ann. Surg. Oncol., 2004, in press.
219. Alexander, H.R.; Bartlett, D.L.; Libutti, S.K.; Fraker, D.L.; Moser, T.; Rosenberg, S.A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol., 1998, 16, 1479-89.
220. Alexander, H.R.; Libutti, S.K.; Bartlett, D.L.; Puhlmann, M.; Fraker, D.L.; Bachenheimer, L.C. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin. Cancer Res., 2000, 6, 3062-70.
221. Bartlett, D.L.; Libutti, S.K.; Figg, W.D.; Fraker, D.L.; Alexander, H.R. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery, 2001, 129, 176-87.
222. Feldman, E.D.; Wu, P.C.; Beresneva, T.; Helsabeck, C.; Rodriguez, M.; Bartlett, D.L.; Libutti, S.K.; Pingpank, J.F.; Alexander, H.R. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J. Gastrointest. Surg., 2004, 8, 200-7.